Illumina Ventures

The company is a genomics and precision health venture firm that supports early-stage companies working to improve human health.

Bill focuses on biotechnology investments and served on Illumina’s board for 17 years, including 10 as chairman. He represents Illumina on GRAIL’s board and chairs Neurocrine Biosciences and Fate Therapeutics.

Ivan is an innovator and entrepreneur with extensive experience in translating early-stage innovations into clinical development programs. As a pharmacologist, Ivan has an appreciation of and insights into the importance of aligning molecular pathways with appropriate therapeutics and diagnostics.

Jerry is executive chairman of Pluton Biosciences, an Illumina Ventures portfolio company that harnesses microbes to develop sustainable solutions for agriculture and climate.

Ronan has more than two decades of experience building companies and selling them to multinationals. His early career included Beverly Records Management, sold to Iron Mountain, and Engage Technologies, sold to Northgate Plc.

Tim was director of the US Food and Drug Administration’s (FDA) Office of In Vitro Diagnostics and has a scientific background in molecular diagnostics, genetics, oncology, and infectious diseases.

Illumina Ventures invests in genomics and precision health and works to build the ecosystem and translate investment into innovation.

Illumina Ventures owns and operates www.illuminaventures.com. Its privacy policy addresses the personal data of investors, founders, and members of the public visiting the site.